INTRODUCTION
Urinary tract infection (UTI) is common in childhood, second only in frequency to that of the respiratory tract [1, 2, 3] . Depending on the localization of the infection (lower or upper urinary tract and renal parenchyma), severity of its clinical presentation and possible acute and long-term complications, UTI may be described as either acute cystitis or as acute pyelonephritis [4] [5] [6] [7] .
Acute pyelonephritis may result in renal scarring, which can predispose patients to longterm complications including toxaemia during pregnancy, hypertension and chronic renal failure later in life. Prompt treatment of childhood acute pyelonephritis is likely to reduce the risk of permanent scarring [8] . Therefore, if there is a high clinical suspicion of acute pyelonephritis, empiric antibiotic therapy is realistic while awaiting urine culture results. When faced with increased urinary pathogen resistance [9, 10] the first choice of an anti-microbial agent for empiric treatment of paediatric UTI is often uncertain.
Based on anti-microbial resistance data in the literature [11] [12] [13] [14] treatment with ceftriaxone (CTX), a third-generation cephalosporin, as preferable empiric therapy has been practiced in children with acute pyelonephritis treated in Serbia from 2005 onwards. However, the emergence of uropathogen strains producing extended spectrum β-lactamases (ESBLs) has threatened the empirical use of third-generation cephalosporins. Despite this, they still appear to be effective in the treatment of UTI. Accordingly, it is not yet clear whether in vitro resistance to CTX determined by standard methods presents an excluding factor for its use as empiric therapy of acute pyelonephritis in children.
OBjECTIvE
The primary objective of this study was to examine in vivo susceptibility of ESBL producing Escherichia coli (E. coli) to ceftriaxone, and secondary to evaluate the options of empiric therapy for acute pyelonephritis in children. Children's Hospital in Belgrade for their first UTI were reviewed. The patients who met the following criteria were included in the study: fever higher than 38.5 °C with no other recognized cause, leukocytosis, C reactive protein (CRP) higher than 20 mg/l, positive dipstick for leukocyte esterase and/or piuria (urine specimen with ≥10 white blood cells (WBC)/(high power field) (hpf), isolation of more than 10 5 colony-forming units (CFUs)/ml of E. coli in a urine sample obtained by midstream clean catch or sterile bags, and empiric antibiotic therapy with CTX. Those receiving antibiotics within the previous 7 days, immunosuppressed children and those with history of previous UTI were excluded from the study. Analyzed data included age, gender, UTI symptoms, treatment and outcome as well as a history of infections, antibiotic therapy and hospitalization during the last 3 months and urinary tract imaging were recorded for each patient. Ultrasonography performed within 72 h of admission into hospital was required for all patients, while voiding cysto-urethrography (VCUG) and Tc-99m DMSA scintigraphy (DMSA scan) were optional at the treating physician's request and parents' decision.
METHODS
All urine samples were obtained in hospital by health care personnel. Contaminated specimens were discarded from the study. Standard methods for isolation and identification of the isolates were used. Anti-bacterial susceptibility testing of the isolates was performed by the standard disc diffusion method as recommended by the Clinical and Laboratory Standards Institute (CLSI) [13] . ESBL phenotypic confirmatory test with ceftazidime, ceftriaxone and cefotaxime was performed for all isolates by disc diffusion method on Mueller-Hinton agar plates. A ≥5 mm increase in a zone diameter for antimicrobial agent tested in combination with clavulanic acid versus its zone when tested alone was considered indicative of ESBL production. The methods used did not vary throughout the study period. No tests were performed to further characterize the clonal origin of isolates.
For all patients repeat urine and urine cultures were performed after 48-72 h and blood WBC and CRP were done within 5-7 days of empiric CTX therapy. The clinical effect of CTX was evaluated by analyzing the response of clinical (fever, WBC and CRP) and urine parameters (urine WBC and urine culture) to empiric CTX therapy. In addition, the clinical outcomes of ESBL (+) and ESBL (-) UTI were compared. A successful treatment (in vivo sensitivity) was defined by resolution of fever, sterile control urine cultures at ≤72 hours and decreasing trend in leucocytes, CRP and urine WBC within 5-7 days.
Statistical analysis
SPSS 13 for Microsoft Windows was used for all statistical analyses. Results for continuous variables were presented as mean (±SEM). The Fisher's exact test was used to compare categorical variables. The Mann-Whitney U test was used for continuous variables. P value <0.05 was considered to be statistically significant. Table  1 . The patients with ESBL (+) UTI were younger and had higher CRP before therapy than the patients with ESBL (-) UTI. Nevertheless, the groups were well-matched according to gender, dose of CTX and to the available data for underlying risk factors for ESBL (+) UTI including renal ultrasound abnormalities, vesicoureteral reflux, infections in the last 3 months, use of antibiotics in the last 3 months, and hospitalization in the last 3 months. Moreover, the clinical parameters of acute pyelonephritis (Table 2) , as well as the percentages of the patients with acute pyelonephritis documented on DMSA scan (Table 1) were similar between the two groups of patients. 
RESULTS

Clinical characteristics
Treatment outcome
All patients received parenteral CTX as empiric therapy at a mean dose of 66.9 mg (range 43-100 mg/kg) during 7.2±2.6 days of therapy. Almost all patients with ESBL (+) UTI (87.5 %) responded by sterilization their urine culture during the first 48-72 h. Therefore, most of them (85.4 %) continued under the same drug even if in vitro resistance was recognized. Clinical effect of CTX was similar in the patients with ESBL (+) compared to those with ESBL (-) UTI (Table 2) .
DISCUSSION
To start empiric therapy of UTI is important in febrile children as the delay of the antibiotic therapy increases the chance of the acute and long term kidney injury [7, 8] . The choice of empiric therapy should be based on the knowledge of E. coli as the most common uropathogen (72-96%) and its antibiotic sensitivities, considering that nowadays ESBL-producing E. coli is on the rise worldwide [12, 13, 16, 17] . At present, most common options for empiric therapy of UTI in children includes third-generations of cephalosporins [11] [12] [13] for which ESBL-E. coli is by definition resistant [18] . In addition, multidrug resistance which is common in ESBL (+) E. coli [17, 19] seriously affects the management of children with UTI. On the other hand, there are restrictions against the routine use of some drugs in paediatric patients due to their side effects, such as are for fluoroquinolones [20] , or due to the limited experience, as is the case for fosfomycin sodium [21] . Currently, carbapenem-resistant E. coli are rarely isolated, but these drugs should be used only for severe acute infections. Consequently, paediatricians are remained with limited options for empiric therapy of acute pyelonephritis in children. Fortunately, the clinical response of ESBL (+) E. coli to antibiotics seems to be much better than their in vitro sensitivity [22, 23] . Although very important from the practical side, this topic remains unclear primarily because there have not been prospective studies designed specifically to evaluate clinical outcomes among a statistically meaningful number of patients with ESBL-producing E. coli. According to the existing data from the literature, it is apparent that there is a disagreement with regard to the role of third-generation cephalosporin treatment in outcome [22, 24] . Although ceftazidime treatment was always associated with treatment failure, a favourable response to treatment with a third-generation cephalosporin other than ceftazidime was observed for cases in which the ESBL was identified as TEM-6 or TEM-12; these 2 ESBLs have relatively weaker hydrolytic activity against extended-spectrum cephalosporins [25] .
Our study is based only on clinical data from practice. Therefore, it lacks the extensive investigations of the genetic and/or enzyme types of E. coli. We examined microbiological in vitro versus clinical in vivo susceptibility of ESBL E. coli to CTX in children with acute pyelonephritis. Our results demonstrated that the clinical response (in vivo sensitivity of E. coli) to CTX was similar in the children with ESBL (+) UTI compared to those with ESBL (-) UTI. More than 80% of patients in whom ESBL-producing E. coli was identified were successfully treated with this drug. Thus, CTX could be effective for the treatment of UTI even when in vitro susceptibility testing suggests ESBL (+) E. coli. It means that in vitro resistance of E. coli to CTX documented by standard methods was not sufficiently predictive for its in vivo resistance. This may be due to the fact that the drug is concentrated in urine, while susceptibility testing is mostly based on blood concentration determinations. Urinary concentrations of anti-microbial agents enable bactericidal levels to be achieved despite apparent in vitro resistance.
According to our findings, CTX may be the first line therapy of acute pyelonephritis in children, although this premise should be analyzed prospectively.
Our analysis has some limitations. The greatest limitation of this study is its retrospective design; it was not possible to identify underlining risk factors associated with ESBL (+) strains for all patients. Also, sterile bags or midstream clean catch urine is not the method of choice to obtain sterile urine in infants and children. However, the strictly matched both groups of patients makes it easier to balance the confounding factors. Urine samples were obtained in hospital by health care personnel and the collections of data as well as the laboratory methods were the same for both groups of patients. In addition, selection criteria included patients in whom the diagnosis of acute pyelonephritis was made solely on clinical grounds, while confirmative renal DMSA scan was done in only one-third of patients in both groups. Nevertheless, according to the results of CRP before therapy, our patients with ESBL (+) UTI had more severe UTI than the patients with ESBL (-), but the response of therapy was comparable in both groups which carried more evidence for in vivo susceptibility of ESBL E. coli to ceftriaxone. Finally, ESBL-producing E. coli testing in our study did not include identification of its enzyme
